These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33966346)

  • 41. Discovery of a series of hydroximic acid derivatives as potent histone deacetylase inhibitors.
    Zhang L; Wang X; Li X; Zhang L; Xu W
    J Enzyme Inhib Med Chem; 2014 Aug; 29(4):582-9. PubMed ID: 24059701
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly.
    Rajendran P; Delage B; Dashwood WM; Yu TW; Wuth B; Williams DE; Ho E; Dashwood RH
    Mol Cancer; 2011 May; 10():68. PubMed ID: 21624135
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plant Derived Inhibitor Sulforaphane in Combinatorial Therapy Against Therapeutically Challenging Pancreatic Cancer.
    Ganai SA; Rashid R; Abdullah E; Altaf M
    Anticancer Agents Med Chem; 2017; 17(3):365-373. PubMed ID: 27281367
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and Evaluation of C15 Triene Urushiol Derivatives as Potential Anticancer Agents and HDAC2 Inhibitor.
    Qi Z; Wang C; Jiang J
    Molecules; 2018 May; 23(5):. PubMed ID: 29751548
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
    Lu A; Luo H; Shi M; Wu G; Yuan Y; Liu J; Tang F
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4924-7. PubMed ID: 21741834
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In silico approaches for investigating the binding propensity of apigenin and luteolin against class I HDAC isoforms.
    Ganai SA; Farooq Z; Banday S; Altaf M
    Future Med Chem; 2018 Aug; 10(16):1925-1945. PubMed ID: 29992822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape.
    Conte M; Dell'Aversana C; Benedetti R; Petraglia F; Carissimo A; Petrizzi VB; D'Arco AM; Abbondanza C; Nebbioso A; Altucci L
    Oncotarget; 2015 Jan; 6(2):886-901. PubMed ID: 25473896
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
    Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
    Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterizing binding intensity and energetic features of histone deacetylase inhibitor pracinostat towards class I HDAC isozymes through futuristic drug designing strategy.
    Ganai SA
    In Silico Pharmacol; 2021; 9(1):18. PubMed ID: 33628709
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular dynamics and quantum chemistry-based approaches to identify isoform selective HDAC2 inhibitor - a novel target to prevent Alzheimer's disease.
    Choubey SK; Jeyakanthan J
    J Recept Signal Transduct Res; 2018 Jun; 38(3):266-278. PubMed ID: 29932788
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
    Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
    Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
    Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
    J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
    Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
    Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Computational design of a time-dependent histone deacetylase 2 selective inhibitor.
    Zhou J; Li M; Chen N; Wang S; Luo HB; Zhang Y; Wu R
    ACS Chem Biol; 2015 Mar; 10(3):687-92. PubMed ID: 25546141
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Histone Deacetylase 2 (HDAC2) Inhibitors Containing Boron.
    Kavianpour P; Gemmell MCM; Kahlert JU; Rendina LM
    Chembiochem; 2020 Oct; 21(19):2786-2791. PubMed ID: 32367603
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
    Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inflammation-mediated deacetylation of the ribonuclease 1 promoter
    Bedenbender K; Scheller N; Fischer S; Leiting S; Preissner KT; Schmeck BT; Vollmeister E
    FASEB J; 2019 Aug; 33(8):9017-9029. PubMed ID: 31039328
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.
    Pinkerneil M; Hoffmann MJ; Deenen R; Köhrer K; Arent T; Schulz WA; Niegisch G
    Mol Cancer Ther; 2016 Feb; 15(2):299-312. PubMed ID: 26772204
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Histone deacetylases inhibitor MS-275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K/Akt/mTOR pathway.
    Ma S; Liu T; Xu L; Wang Y; Zhou J; Huang T; Li P; Liu H; Zhang Y; Zhou X; Cui Y; Zang X; Wang Y; Guan F
    J Cell Physiol; 2019 Dec; 234(12):22400-22410. PubMed ID: 31120582
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
    Mendoza-Sanchez R; Cotnoir-White D; Kulpa J; Jutras I; Pottel J; Moitessier N; Mader S; Gleason JL
    Bioorg Med Chem; 2015 Dec; 23(24):7597-606. PubMed ID: 26613635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.